Adiponectin for treatment of various disorders
View Patent ↗Methods for treating various disorders by orally administering adiponectin or a biologically active fragment thereof are described.
1. A method for treating or reducing the risk of necrotizing enterocolitis comprising administering to an infant a composition containing a purified polypeptide that includes the amino acid sequence of an adiponectin or a biologically active fragment thereof, which is selected from the group consisting of 84-244, 85-244, 86-244, 87-244, 88-244, 89-244, 90-244, 91-244, 92-244, 93-244, 94-244, 95-244, 96-244, 97-244, 98-244, 99-244, 100-244, 101-244, 102-244, 103-244, 104-244, 105-244, 106-244, 107-244, 108-244, 109-244, 110-244, and 111-244 of SEQ ID NO: 1.
2. The method of claim 1 , wherein the infant was born prematurely.
3. The method of claim 1 , wherein the polypeptide is glycosylated and optionally hydroxylated.
4. The method of claim 1 , wherein the polypeptide is an adiponectin or the biologically active fragment thereof.
5. The method of claim 4 , wherein the composition further comprises lactose.
6. The method of claim 1 , wherein the composition further comprises one or more oligosaccharides found in human milk, which are selected from the group consisting of facto-N-fucopentaose I [LNF-I], 2-fucosyllactose [2′-FL], lacto-N-difucohexaose I [LDFH-I], lactodifucotetraose [LDFT]), lacto-N-fuco-pentaose II [LNF-II], 3-fucosyllactose [3-FL], lacto-N-fucopentaose III [LNF-III], facto-N-tetraose [LNT], and lacto-N-neotetraose [LNneoT].
7. The method of claim 4 , wherein the adiponectin is in the form found in human milk.
8. The method of claim 4 , wherein the polypeptide is an adiponectin and the composition is administered at an amount to achieve a plasma concentration of the adiponectin between 1 μg/ml and 100 μg/ml.
9. The method of claim 4 , wherein the adiponectin is in a complex containing at least two molecules of the adiponectin.
10. The method of claim 1 , wherein the adiponectin or the biologically active fragment thereof is modified by at least one moiety selected from the group consisting of glucosylgalactosyl moiety, glucosylglucosyl moiety, galactosylglucosyl moiety, and galactosylgalactosyl moiety.
11. The method of claim 1 , wherein the composition is administered orally.